

June 1, 2021

To,
SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sir,

Sub: Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH
VINAYAK KUBER

Digitally signed by
HARISH VINAYAK KUBER
Date: 2021.06.01
10:01:52 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Press Release

For Immediate Release

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

Mumbai, India, June 1, 2021: – Glenmark Pharmaceuticals Limited (Glenmark) has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel®¹ Tablets, 200 mg and 400 mg of Eisai, Inc. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on May 16, 2016.

Commenting on the launch, Sanjeev Krishan, President, Glenmark North America said, “We are very pleased to be one of the first generic companies in the US to offer lower cost alternative to Banzel® Tablets, 200 mg and 400 mg. The launch is our commitment to provide quality and affordable healthcare to our markets for patients.”

According to IQVIA™ sales data for the 12 month period ending April 2021, the Banzel® Tablets, 200 mg and 400 mg market² achieved annual sales of approximately \$285.3 million*.

Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

--End--

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index.

For more information, visit www.glenmarkpharma.com

For further information, please contact:

Udaykumar Murthy

Senior Manager, Corporate Communications

Glenmark, Mumbai, India

Tel: +91 9960377617

Email: corpcomm@glenmarkpharma.com

References:

¹All brand names and trademarks are the property of their respective owners.

²Market includes brand and all available therapeutic equivalents

*IQVIA™ National Sales Perspectives: Retail & Non-Retail, April 2021